We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600383:SSEGemdale Corporation Class A Analysis

Data as of 2026-03-17 - not real-time

CN¥3.13

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Gemdale Corporation trades at CNY 3.13, hovering just above the calculated support of 3.03 and well below its 52‑week high of 5.26. The price sits between the 20‑day SMA (3.21) and 50‑day SMA (3.19), indicating a neutral trend, while the 200‑day SMA (3.68) remains above current levels, suggesting long‑term weakness. Technical momentum is bearish, with the MACD line below its signal and a negative histogram, and the RSI at 45.6 points to a lack of bullish pressure.
Fundamentally, the firm is under severe strain: revenue plunged 58% YoY, margins are deeply negative (gross 9.3%, operating ‑9.3%, profit ‑12.3%), and earnings per share are negative. The balance sheet shows a high debt‑to‑equity ratio of 72.6% and a debt load of CNY 69.3 bn versus cash of CNY 14.3 bn, though operating cash flow remains positive at CNY 4.35 bn. Valuation metrics are distorted—PE is negative, while the price‑to‑book ratio of 0.26 hints at a potential asset‑value discount, but the company’s earnings outlook and sector headwinds temper any upside.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support with limited upside
  • Bearish MACD and neutral RSI
  • High debt burden limiting near‑term flexibility

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Continued revenue contraction and negative margins
  • Positive operating cash flow but constrained by leverage
  • Sector‑wide slowdown and regulatory pressures in Chinese real estate

Long Term

> 3 years
Cautious
Model confidence: 3/10

Key Factors

  • Structural challenges in the Chinese property market
  • Elevated debt‑to‑equity ratio and large max drawdown (~40%)
  • Lack of dividend and unclear path to profitability

Key Metrics & Analysis

Financial Health

Revenue Growth-58.20%
Profit Margin-12.34%
P/E Ratio-3.3
ROE-7.98%
ROA-0.16%
Debt/Equity72.55
P/B Ratio0.3
Op. Cash FlowCN¥4.3B
Free Cash FlowCN¥2.0B
Industry P/E32.9

Technical Analysis

TrendNeutral
RSI45.6
SupportCN¥3.03
ResistanceCN¥3.51
MA 20CN¥3.21
MA 50CN¥3.19
MA 200CN¥3.68
MACDBearish
VolumeDecreasing
Fear & Greed Index81.48

Valuation

GradeFair
TypeValue

Risk Assessment

Beta0.06
Volatility43.56%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.